Analysis of the cytotoxic activity of carboplatin and gemcitabine combination
- PMID: 21115908
- PMCID: PMC4562399
Analysis of the cytotoxic activity of carboplatin and gemcitabine combination
Abstract
Aim: To determine if the drug doses and administration schedules of carboplatin and gemcitabine combination affect antitumor effects.
Materials and methods: The inhibition of cell viability was measured by MTT assay. Median effect analysis was conducted to determine the cytotoxicity activity of carboplatin and gemcitabine combination. Cell cycle changes were analyzed by flow cytometry.
Results: Synergism was observed when the bladder cancer cell line 5637 cells were treated with gemcitabine followed by carboplatin or concurrent carboplatin/gemcitabine. In contrast, moderate antagonism was observed when cells were treated with carboplatin followed by gemcitabine. Cell cycle analysis showed that the combined effect of these two drugs was cell cycle disturbance.
Conclusion: Different doses and administration schedules affect the antitumor effect of carboplatin/gemcitabine combination that may have clinical significance in the treatment for bladder cancer.
Figures


Similar articles
-
Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells.Chem Res Toxicol. 2010 Nov 15;23(11):1653-5. doi: 10.1021/tx1003547. Epub 2010 Oct 28. Chem Res Toxicol. 2010. PMID: 21028869 Free PMC article.
-
Anti-tumor effects and cell motility inhibition of the DN604-gemcitabine combined treatment in human bladder cancer models.Bioorg Med Chem. 2021 Jan 1;29:115858. doi: 10.1016/j.bmc.2020.115858. Epub 2020 Nov 7. Bioorg Med Chem. 2021. PMID: 33218897
-
Synergistic antitumour effects of triptolide plus gemcitabine in bladder cancer.Biomed Pharmacother. 2018 Oct;106:1307-1316. doi: 10.1016/j.biopha.2018.07.083. Epub 2018 Jul 21. Biomed Pharmacother. 2018. PMID: 30119201
-
Gemcitabine in bladder cancer.Expert Opin Pharmacother. 2007 Dec;8(18):3251-6. doi: 10.1517/14656566.8.18.3251. Expert Opin Pharmacother. 2007. PMID: 18035967 Review.
-
Gemcitabine/carboplatin in advanced urothelial cancer.Semin Oncol. 2001 Jun;28(3 Suppl 10):19-24. doi: 10.1053/sonc.2001.22537. Semin Oncol. 2001. PMID: 11510030 Review.
Cited by
-
The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.Clin Cancer Res. 2017 Nov 1;23(21):6580-6591. doi: 10.1158/1078-0432.CCR-17-0033. Epub 2017 Aug 14. Clin Cancer Res. 2017. PMID: 28808038 Free PMC article.
-
Combination cytotoxicity of backbone degradable HPMA copolymer gemcitabine and platinum conjugates toward human ovarian carcinoma cells.Eur J Pharm Biopharm. 2014 May;87(1):187-96. doi: 10.1016/j.ejpb.2013.11.008. Epub 2013 Dec 4. Eur J Pharm Biopharm. 2014. PMID: 24316339 Free PMC article.
-
Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy.PLoS One. 2015 Aug 13;10(8):e0134346. doi: 10.1371/journal.pone.0134346. eCollection 2015. PLoS One. 2015. PMID: 26270481 Free PMC article. Clinical Trial.
-
Unraveling BOLD-100 synergistic potential in pleural mesothelioma treatment: an in vitro study.Invest New Drugs. 2025 Jun;43(3):634-645. doi: 10.1007/s10637-025-01540-9. Epub 2025 May 8. Invest New Drugs. 2025. PMID: 40338466 Free PMC article.
-
Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer.Br J Cancer. 2023 May;128(10):1964-1975. doi: 10.1038/s41416-023-02226-w. Epub 2023 Mar 20. Br J Cancer. 2023. PMID: 36941406 Free PMC article.
References
-
- von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;2000;18:3068–3077. - PubMed
-
- Linardou H, Aravantinos G, Efstathiou E, Kalofonos C, Anagnostopoulos A, Deliveliotis C, Bafaloukos D, Athanasios Dimopoulos M, Bamias A. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced with bladder carcinoma: phase II study of the hellenic cooperative oncology group. Urology. 2004;2004;64:479–484. - PubMed
-
- Bajetta E, Stani SC, De Candis D, Zaffaroni N, Zilembo N, Cortinovis D, Aglione S, Mariani L, Formisano B, Bidoli P. Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer. European Society for Medical Oncology. 2003;2003;14:242–247. - PubMed
-
- Hudson E, Lester JF. Gemcitabine and carboplatin in the treatment of transitional cell carcinoma of the urothelium: a single centre experience and review of the literature. Eur J Cancer Care. 2010;2010;19:324–328. - PubMed
-
- Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;2002;346:92–98. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical